SNIPR Biome ApS (“SNIPR”), the company pioneering the development of microbial CRISPR-medicine, today announced the close of a EUR 35 million Series B raise with funding from new investors the Cystic ...

The FDA decision follows the announcement in July by the European Medicines Agency (EMA) 1 which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough ...

Strong underlying sales growth was underpinned by the double-digit performance from our biosimilars which, in the second quarter, represented 30% of net sales for the first time, marking a true ...

The conference call will be held on Thursday, 28 August 2025 at 3pm CEST / 2pm BST / 9am EDT / 6am PDT as a Teams webinar. To attend the webcast, register via this link. Please complete the ...

In a release issued under the same headline on August 6, 2025 by Inotiv, Inc. (NASDAQ: NOTV), please note that the amount of the recent draw request on the revolving credit facility has been corrected ...

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, ...

Total revenue of $8.5 million in the second quarter of 2025, a decrease of 18% over the second quarter of 2024. MaxCyte added two new SPL clients, Adicet Bio and Anocca AB, in July. Including TG ...

SAN DIEGO, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class WEE1 ...

The conference call can be accessed using the following information: Webcast: Click here Date: Wednesday, August 13, 2025 – 4:30 p.m. ET Domestic: (877) 407-0832 International: (201) 689-8433 ...

CARLSBAD, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, today announced that management will participate in the following ...

Third quarter fiscal 2025 revenue up 23.5% to $130.7 million – Year-to-date fiscal 2025 revenue increased 4.0% to $374.9 million – Conference call scheduled for today at 4 ...

“We’re thrilled to welcome Dr. Tarnoff to our Board during this pivotal phase of growth,” said Jim Corbett, Chief Executive Officer of AVITA Medical. “His leadership and expertise in clinical ...